Everstone Capital has invested Rs 220 crore in contract research and drug delivery company Rubicon Research, the latest investment by the mid-market private equity firm, as it steps up its deal making pace, and continues to diversify its portfolio.
The $33 million investment, which has both, primary and secondary components, will also provide Kotak Private Equity, an early investor in Mumbai-based Rubicon Research, a full exit from the company, having invested Rs 60 crore till date. Post this transaction, Everstone will own a 70% stake in Rubicon. “Rubicon has an excellent record of providing cutting-edge solutions to the healthcare and pharmaceutical industry. We are excited about enhancing its capabilities,” said Sameer Sain, managing partner of the Everstone Group.